Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

With the first half of 2022 proving difficult for biotech companies’ share prices, we are now seeing a rebound. Daniel Koller gives his views on industry trends and where BB Biotech fits in.

Interview Edison Group with Dr. Daniel Koller

With the first half of 2022 proving difficult for biotech companies’ share prices, we are now seeing a rebound. Daniel Koller gives his views on industry trends and where BB Biotech fits in.
08.09.2022 - Daniel Koller